title: Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.
abstract: The licensure of new pneumococcal conjugate vaccines (PCVs) relies on immunogenicity data. When defining correlates of protection, vaccine efficacy data must be included. In the FinOM Vaccine Efficacy Trial, the PncOMPC vaccine showed an efficacy profile similar to that of the licensed PncCRM vaccine despite different antibody responses after primary and booster vaccinations. We determined antibody kinetics and avidities in a subgroup of infants participating in the FinOM trial. A total of 166 infants in three vaccine groups were immunized at 2, 4, 6, and 12 months of age with 7-valent PCV, PncCRM or PncOMPC, or hepatitis B vaccine. Concentrations of serum immunoglobulin G (IgG) against pneumococcal capsular polysaccharides were determined at 2, 4, 6, 7, 12, 13, and 24 months of age, and the avidity index (AI) to serotypes 6B, 19F, and 23F were determined at 7, 12, 13, and 24 months of age by enzyme immunoassay. Both PCVs were highly immunogenic, but they demonstrated different kinetics of antibody response; the concentration of IgG against serotypes 6B, 19F, and 23F declined faster after the third and fourth doses of vaccine in the PncCRM group than in the PncOMPC group. For both PCVs, the mean AI of anti-6B and -23F, but not of anti-19F, increased during the follow-up, which is in line with serotype-specific protection in the FinOM trial. Our data suggest that the kinetics and avidities of antibodies should be considered, in addition to antibody responses, when defining correlates of protection.
authors.affiliation: Vaccine Immunology Laboratory, National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland. nina.ekstrom@ktl.fi
authors.forename: Nina
authors.initials: N
authors.lastname: Ekström
authors.forename: Heidi
authors.initials: H
authors.lastname: Ahman
authors.forename: Jouko
authors.initials: J
authors.lastname: Verho
authors.forename: Jukka
authors.initials: J
authors.lastname: Jokinen
authors.forename: Merja
authors.initials: M
authors.lastname: Väkeväinen
authors.forename: Terhi
authors.initials: T
authors.lastname: Kilpi
authors.forename: Helena
authors.initials: H
authors.lastname: Käyhty
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D000915:Antibody Affinity; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007700:Kinetics; D022401:Meningococcal Vaccines / Q000276:immunology*; D010033:Otitis Media / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D007074:Immunoglobulin G; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines